- Home
- SOGP vs SNGX Comparison
SOGP vs SNGX Comparison
Compare SOGP & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOGP
- SNGX
- Stock Information
- Founded
- SOGP 2010
- SNGX 1987
- Country
- SOGP Singapore
- SNGX United States
- Employees
- SOGP N/A
- SNGX N/A
- Industry
- SOGP
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- SOGP
- SNGX Health Care
- Exchange
- SOGP NYSE
- SNGX Nasdaq
- Market Cap
- SOGP 6.9M
- SNGX 6.5M
- IPO Year
- SOGP 2020
- SNGX 1987
- Fundamental
- Price
- SOGP $1.33
- SNGX $1.93
- Analyst Decision
- SOGP
- SNGX
- Analyst Count
- SOGP 0
- SNGX 0
- Target Price
- SOGP N/A
- SNGX N/A
- AVG Volume (30 Days)
- SOGP 10.2K
- SNGX 18.1K
- Earning Date
- SOGP 06-17-2025
- SNGX 05-09-2025
- Dividend Yield
- SOGP N/A
- SNGX N/A
- EPS Growth
- SOGP N/A
- SNGX N/A
- EPS
- SOGP N/A
- SNGX N/A
- Revenue
- SOGP $278,363,908.00
- SNGX $2,342.00
- Revenue This Year
- SOGP $48.88
- SNGX N/A
- Revenue Next Year
- SOGP N/A
- SNGX N/A
- P/E Ratio
- SOGP N/A
- SNGX N/A
- Revenue Growth
- SOGP N/A
- SNGX N/A
- 52 Week Low
- SOGP $1.18
- SNGX $1.68
- 52 Week High
- SOGP $2.58
- SNGX $14.83
- Technical
- Relative Strength Index (RSI)
- SOGP 43.20
- SNGX 49.95
- Support Level
- SOGP $1.20
- SNGX $1.86
- Resistance Level
- SOGP $1.32
- SNGX $1.97
- Average True Range (ATR)
- SOGP 0.06
- SNGX 0.09
- MACD
- SOGP 0.04
- SNGX 0.01
- Stochastic Oscillator
- SOGP 85.14
- SNGX 70.59
About SOGP SOUND GROUP INC SPON ADS EA REP 200 ORD SHS(POST SPLIT)
Sound Group Inc is a world-wide audio-centric social and entertainment company. It Leverages broad product portfolio and in-house technologies, Sound Group caters to user interest in audio entertainment and social networking. Sound Group nurtures a globally diverse and inclusive team, drawing on talent from various countries and regions world-wide.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).